Voluntis Extends Partnership with AstraZeneca in Digital Therapeutics for Oncology
Regulatory News:
Voluntis (Paris:VTX), a digital biotech specialized in digital therapeutics, has announced the extension of its collaboration
with AstraZeneca (NYSE: AZN) in the field of oncology. As part of the renewed agreement, the partners will implement a new phase of
clinical evaluation of their digital therapeutic designed to support platinum resistant ovarian cancer patients treated with a
combination of Cediranib plus Olaparib.
The eCO (eCediranib/Olaparib) solution will be tested in the GY005 randomized phase III clinical trial sponsored by the National
Cancer Institute (NCI), which will evaluate if the digital therapeutic can complement treatment by determining whether it enables
better management of side effects and thereby improves patient outcomes. Women and their clinicians will be given eCO in
conjunction with their Cediranib and Olaparib treatment to help manage symptoms of hypertension and diarrhea sometimes associated
with their therapy to enable them to stay longer on treatment. Patients will access eCO through a smartphone app in which they can
record their symptoms to receive real-time recommendations. Clinicians will be able to use a corresponding web portal to track
their patient population remotely and adjust symptom management plans as necessary.
“We are delighted to build upon the promising results of our first clinical trial, begun in 2015, and take our innovative
partnership with AstraZeneca one step further to study the impact of our eCO solution on a larger scale, using our state-of-the-art
Theraxium platform,” said Pierre Leurent, CEO of Voluntis. “Digital therapeutics, like eCO, are at the forefront of a new
generation of digital solutions, developed in conjunction with medications as early as Phase II/III trials. Through this new phase
of our collaboration, we look forward to providing access to this solution to more patients and, hopefully, help them enjoy a
better quality of life and treatment outcome.”
Through the extended agreement, the eCO solution will also be migrated to Theraxium Oncology, Voluntis’ new platform for digital
therapeutics in oncology announced earlier this year.
About eCO
eCO (eCediranib/Olaparib) is a digital therapeutic for women undergoing treatment for recurrent platinum-sensitive high-grade
ovarian cancer in clinical trials of Cediranib plus Olaparib. Voluntis developed the service in close clinical collaboration with
AstraZeneca and the National Cancer Institute (NCI) beginning in 2015. Initial results communicated at ESMO 2017 with the NCI
confirmed high adherence, usability and satisfaction. In this clinical evaluation, eCO successfully supported remote monitoring of
hypertension and diarrhea events for sixteen women with advanced ovarian cancer treated with a combination of Cediranib and
Olaparib (JCO Clinical Cancer Informatics 2018). The women self-reported a total of 98.2% of expected home blood pressure values
using a Bluetooth connected blood pressure cuff in 94.2% of instances. For diarrhea, thirteen patients reported 33 entries, none of
which advanced past grade 2. Patients reported overall high usability (ease of learning and ease of use) and satisfaction with eCO,
especially feeling closely monitored, more connected to their health care team and greater involvement in their own self-care.
About Voluntis
Voluntis creates digital therapeutics that empower people suffering from chronic conditions to self-manage their treatment every
day, thus improving real-world outcomes. Combining mobile and web apps, Voluntis’ solutions deliver personalized recommendations to
the patient and the care team that so that they can, for example, adjust treatment dosage, manage side effects or monitor symptoms.
These real-time recommendations are based on digitized clinical algorithms. Leveraging its Theraxium technology platform, Voluntis
has designed and operates multiple digital therapeutics. These include Insulia® and Diabeo® in diabetes as
well as eCO and ZEMY in oncology. Voluntis has long-standing partnerships with leading life science companies such as Roche,
AstraZeneca, Sanofi and Onduo. Based out of Boston and Paris, France, Voluntis is a founding member of the Digital Therapeutics
Alliance.
Diabeo® is a registered trademark of Sanofi. Insulia® is a registered trademark of Voluntis.
For further information: http://www.voluntis.com
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20180830005499r1&sid=mstr3&distro=nx&lang=en)
Voluntis
Amelie Janson
Communications Manager
press@voluntis.com
+33 (0)1 41 38 39 20
or
NewCap
Investor relations
Marc Willaume/Tristan Roquet Montégon
voluntis@newcap.eu
+33 (0)1 44 71 94 94
or
NewCap
Media relations
Nicolas Merigeau
voluntis@newcap.eu
+33 (0)1 44 71 94 98
View source version on businesswire.com: https://www.businesswire.com/news/home/20180830005499/en/